Cervomed Inc (CRVO) Stock Price, Quote & News

Company Profile

CervoMed Inc., a a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule brain penetrant that inhibits p38 mitogen-activated protein kinase alpha. Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that cause disease in DLB and certain other major neurologic...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 744 4400

Website: www.cervomed.com

Address:

20 Park Plaza, Suite 424, Boston, United States

BPler Feb. 20 at 8:38 AM

$CRVO DD would need an even bullisher update, but I like the PTs range for H2 https://www.reddit.com/r/pennystocks/comments/1qq3xv9/dd_crvo_cervomed_inc/

0 · Reply

BPler Feb. 19 at 7:05 PM

$ALMS is one of the best example for a biotech rocketing even with an offering as the company value was undervalued for years until the takeoff and news. Great example of know what you own. Hope to see this with $CRVO with Phase 3 alignment and yesterdays use that https://www.biospace.com/press-releases/cervomeds-neflamapimod-elected-for-inclusion-in-uk-experts-als-platform-designed-to-prioritize-promising-treatments-for-amyotrophic-lateral-sclerosis

0 · Reply

LowCountryHooker Feb. 19 at 2:40 PM

$CRVO We’re thrilled that neflamapimod has been selected by the UK’s EXPERTS-ALS platform to assess its potential as an ALS treatment. Funded by the UK government and leading motor neuron disease charities, EXPERTS-ALS conducts an ongoing clinical trial at sites throughout the UK to rapidly identify promising drug candidates and expedite their development. Neflamapimod was selected based on its mechanism of action, demonstrated clinical activity in neurodegenerative diseases, and encouraging translational data in relevant neurotoxicity models. This will be the first clinical study to evaluate neflamapimod in ALS. ALS is a devastating disease for people with the condition and their families, and we’re proud to partner with EXPERTS-ALS. You can read more here: https://lnkd.in/e455yvzN #ALS #neflamapimod

0 · Reply

BPler Feb. 19 at 2:05 PM

$CRVO From updated company deck

1 · Reply

MV0527 Feb. 19 at 1:16 PM

$CRVO Another disease Crvo can impact. Rev Jesse Jackson had this. Tau proteins are involved in so many medical issues. This could be huge after phase 3.

0 · Reply

BPler Feb. 18 at 3:42 PM

$CRVO Added for 1.000€ The potential in Neflamapimod is too huge and market cap too low.

0 · Reply

BPler Feb. 18 at 2:34 PM

$CRVO PT 31 USD https://www.gurufocus.com/news/8626948/cervomed-crvo-analyst-rating-maintained-as-buy-by-d-boral-capital-crvo-stock-news

0 · Reply

BPler Feb. 18 at 2:20 PM

Congrats had a small position in $SNSE, now waitting for $CRVO to catchup

1 · Reply

BPler Feb. 18 at 12:06 PM

$CRVO "UK-based trial first to evaluate neflamapimod in ALS; first person with ALS expected to be dosed by end of 2026" https://finance.yahoo.com/news/cervomed-neflamapimod-elected-inclusion-uk-110000785.html

1 · Reply

BPler Feb. 18 at 11:44 AM

$CRVO BOSTON, Feb. 18, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders, today announced that neflamapimod, an oral small molecule drug candidate targeting critical disease processes underlying degenerative disorders of the brain, has been selected for inclusion in the EXPERTS-ALS platform. EXPERTS-ALS facilitates rapid testing of potential treatments for amyotrophic lateral sclerosis (ALS) to identify promising drug candidates and potentially accelerate their path to regulatory approval. Funded by the United Kingdom (UK) National Institute for Health and Care Research (NIHR) and leading motor neuron disease charities (...) https://ir.cervomed.com/news-releases/news-release-details/cervomeds-neflamapimod-elected-inclusion-uk-experts-als-platform

1 · Reply

CERo Therapeutics Announces Biotech Industry Veteran Eric Francois to Join its Board of Directors

SCYX

Dec 4, 2025, 5:00 PM EST - 2 months ago

CervoMed Announces Late-Breaking Data at the 18th CTAD Conference Demonstrating Neflamapimod Significantly Slows Clinical Progression in Dementia with Lewy Bodies

Dec 2, 2025, 7:00 AM EST - 2 months ago

CervoMed Presents New Plasma Biomarker Data That Indicates Neflamapimod Broadly Improves Neuroinflammation and Neurodegeneration in Dementia with Lewy Bodies (DLB)

Nov 24, 2025, 7:00 AM EST - 3 months ago

CervoMed to Share New Data on Neflamapimod as a Treatment for Dementia with Lewy Bodies at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference

Oct 20, 2025, 8:00 AM EDT - 4 months ago

CervoMed to Present at the Emerging Growth Conference

Oct 8, 2025, 11:54 AM EDT - 4 months ago

CervoMed Drug Cut Dementia Progression Risk By 75% In Trial

Oct 8, 2025, 7:00 AM EDT - 4 months ago

CervoMed Announces New Data from Phase 2b Trial Demonstrating Neflamapimod's Potential as a Treatment for Dementia with Lewy Bodies

Oct 2, 2025, 8:00 AM EDT - 5 months ago

CervoMed to Participate in the 4th Annual ROTH Healthcare Opportunities Conference

Sep 17, 2025, 7:30 AM EDT - 5 months ago

CervoMed Highlights Neflamapimod's Potential Benefits in Session on Dementia with Lewy Bodies at the 150th Annual American Neurology Association Conference

Sep 3, 2025, 8:00 AM EDT - 6 months ago

CervoMed to Participate in Upcoming Investor Conferences

Jul 28, 2025, 11:20 AM EDT - 7 months ago

CervoMed's Dementia Data Show Slowed Disease Progression

Jul 28, 2025, 7:00 AM EDT - 7 months ago

CervoMed Announces 32-Week Data from RewinD-LB Trial Extension Phase Showing Neflamapimod's Sustained Effect on Slowing Clinical Progression in Patients with Dementia with Lewy Bodies and Associated Reduction in a Key Plasma Biomarker of Neurodegeneration

Jul 8, 2025, 7:00 AM EDT - 8 months ago

CervoMed Announces Late-Breaking Presentations at Alzheimer's Association® International Congress 2025

May 12, 2025, 8:00 AM EDT - 10 months ago

CervoMed Reports First Quarter 2025 Financial Results and Provides Corporate Updates

Mar 31, 2025, 2:34 PM EDT - 11 months ago

Biotech Stocks Q1 2025 Recap: Winners And Underperformers

CMRX CVS GERN LLY NVO SEPN

Mar 25, 2025, 8:00 AM EDT - 11 months ago

CervoMed Announces Oral Presentation at 19th International Conference on Alzheimer's and Parkinson's Diseases and Related Neurologic Disorders (AP/PD™)

Mar 22, 2025, 2:55 AM EDT - 11 months ago

CervoMed: Extension Study Data In Dementia With Lewy Bodies Is Potentially Exciting, With Caveats

Mar 10, 2025, 4:05 PM EDT - 1 year ago

CervoMed Announces Positive Results from the Extension Phase of its Phase 2b Clinical Study of Neflamapimod in Patients with Dementia with Lewy Bodies

Jan 29, 2025, 8:00 AM EST - 1 year ago

CervoMed to Present at the 8th International Lewy Body Dementia Conference

Dec 12, 2024, 7:00 AM EST - 1 year ago

CervoMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dec 10, 2024, 11:37 AM EST - 1 year ago

CervoMed's Dementia Candidate Fails In Mid-Stage Study, Stock Plummets

Dec 10, 2024, 10:10 AM EST - 1 year ago

CervoMed's stock craters 77% after failed trial of treatment for rare brain disease

Dec 10, 2024, 7:33 AM EST - 1 year ago

CervoMed's dementia drug fails to meet mid-stage trial goals

Dec 10, 2024, 7:00 AM EST - 1 year ago

CervoMed Announces Topline Data from RewinD-LB Phase 2b Clinical Trial in Patients with Dementia with Lewy Bodies

Nov 27, 2024, 7:00 AM EST - 1 year ago

CervoMed Announces Orphan Drug Designation Granted to Neflamapimod by U.S. Food and Drug Administration for the Treatment of Frontotemporal Dementia

Nov 12, 2024, 7:00 AM EST - 1 year ago

CervoMed Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

Nov 8, 2024, 9:55 AM EST - 1 year ago

CervoMed Awarded the Prix Galien USA 2024 Prize for Best Startup

Nov 4, 2024, 8:00 AM EST - 1 year ago

CervoMed Announces Key Takeaways from Oral Presentations at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD)

Oct 29, 2024, 8:00 AM EDT - 1 year ago

CervoMed to Deliver Oral Presentation at the 8th International Lewy Body Dementia Conference

Oct 2, 2024, 8:00 AM EDT - 1 year ago

CervoMed to Participate in 3rd Annual ROTH Healthcare Opportunities Conference

Aug 22, 2024, 8:00 AM EDT - 1 year ago

CervoMed Featured in Fortune for Advances in the Treatment of Dementia with Lewy Bodies

Jul 30, 2024, 8:00 AM EDT - 1 year ago

CervoMed to Participate in The Canaccord Genuity 44th Annual Growth Conference

Jul 17, 2024, 8:00 AM EDT - 1 year ago

CervoMed to Participate in the Emerging Growth Conference

Jul 11, 2024, 8:51 AM EDT - 1 year ago

CervoMed to Host Virtual KOL Event on Neflamapimod for Dementia with Lewy Bodies on July 23, 2024

Jun 11, 2024, 8:00 AM EDT - 1 year ago

CervoMed Announces Completion of Enrollment in Phase 2b RewinD-LB Clinical Trial of Neflamapimod for the Treatment of Patients with Dementia with Lewy Bodies

May 20, 2024, 8:00 AM EDT - 1 year ago

CervoMed to Appoint William Elder as Chief Financial Officer

May 15, 2024, 8:00 AM EDT - 1 year ago

CervoMed Reports First Quarter 2024 Financial Results and Provides Corporate Updates

Apr 2, 2024, 2:59 AM EDT - 2 years ago

CervoMed: H2 2024 Data For DLB Program A Major Inflection Point

Apr 1, 2024, 8:00 AM EDT - 2 years ago

CervoMed Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates

Mar 28, 2024, 8:30 AM EDT - 2 years ago

CervoMed Announces Up to $149.4 Million Private Placement Financing Joined by Leading Healthcare Investors

Mar 5, 2024, 8:00 AM EST - 2 years ago

CervoMed Announces Presentation of Biomarker Data from the AscenD-LB Phase 2a Trial and Preclinical Data Supporting Potential of Neflamapimod in Tau-Mediated Disease at AD/PD ™ 2024

Feb 21, 2024, 8:00 AM EST - 2 years ago

CervoMed to Participate in the BIO CEO and Investor Conference

Feb 12, 2024, 8:00 AM EST - 2 years ago

CervoMed Publishes Positive Results from AscenD-LB Phase 2a Trial in Peer-Reviewed Journal that Supports the Therapeutic Potential of Neflamapimod in Dementia with Lewy Bodies

Feb 7, 2024, 8:30 AM EST - 2 years ago

CervoMed Announces Appointment of Industry Leader Joshua Boger, Ph.D., as Chair of the Board

Feb 5, 2024, 8:00 AM EST - 2 years ago

CervoMed to Participate in the Emerging Growth Conference 67

Jan 5, 2024, 8:00 AM EST - 2 years ago

CervoMed to Participate in the Emerging Growth Conference 66

Nov 13, 2023, 7:00 AM EST - 2 years ago

CervoMed Reports Third Quarter 2023 Financial Results and Business Highlights

Oct 25, 2023, 2:50 PM EDT - 2 years ago

CervoMed Announces Oral Presentation at CTAD 2023 Highlighting Learnings from Phase 2a Which Optimized the Design of the Phase 2b Clinical Study of Neflamapimod in Dementia with Lewy Bodies

Oct 24, 2023, 7:00 AM EDT - 2 years ago

CervoMed Announces Publications in Major Peer-Reviewed Journals That Inform on Potential of Neflamapimod as a Disease-Modifying Therapy for the Major Dementias

Oct 18, 2023, 7:00 AM EDT - 2 years ago

CervoMed Announces Oral Presentation at CTAD 2023 Highlighting Phase 2b Neflamapimod Program for the Treatment of Patients with Dementia with Lewy Bodies

BPler Feb. 20 at 8:38 AM

$CRVO DD would need an even bullisher update, but I like the PTs range for H2 https://www.reddit.com/r/pennystocks/comments/1qq3xv9/dd_crvo_cervomed_inc/

0 · Reply

BPler Feb. 19 at 7:05 PM

0 · Reply

LowCountryHooker Feb. 19 at 2:40 PM

0 · Reply

BPler Feb. 19 at 2:05 PM

$CRVO From updated company deck

1 · Reply

MV0527 Feb. 19 at 1:16 PM

$CRVO Another disease Crvo can impact. Rev Jesse Jackson had this. Tau proteins are involved in so many medical issues. This could be huge after phase 3.

0 · Reply

BPler Feb. 18 at 3:42 PM

$CRVO Added for 1.000€ The potential in Neflamapimod is too huge and market cap too low.

0 · Reply

BPler Feb. 18 at 2:34 PM

$CRVO PT 31 USD https://www.gurufocus.com/news/8626948/cervomed-crvo-analyst-rating-maintained-as-buy-by-d-boral-capital-crvo-stock-news

0 · Reply

BPler Feb. 18 at 2:20 PM

Congrats had a small position in $SNSE, now waitting for $CRVO to catchup

1 · Reply

BPler Feb. 18 at 12:06 PM

1 · Reply

BPler Feb. 18 at 11:44 AM

1 · Reply

BPler Feb. 18 at 10:20 AM

$CRVO Instutional Ownership and latest buying is not really shown in price movement. Adding a bit weekly until earnings, with these prices I average down gladly.

0 · Reply

Messerschmittbf109 Feb. 17 at 8:38 PM

$CRVO $CRDF This was last end dicember r@tt. Ens Cantor Fitzgerald initiated coverage of CervoMed (NASDAQ:CRVO) with an Overweight rating on Thursday. The stock, currently trading at $7.99, appears slightly undervalued according to InvestingPro's Fair Value estimates, with analyst price targets ranging from $15 to $31.

0 · Reply

Messerschmittbf109 Feb. 17 at 6:12 PM

$CRDF $BBNX $CRVO One two three … 3️⃣ disgusting stocks CEO should ask himself some questions in front of the mirror... shame on him or her!

0 · Reply

GlobalMacroTactics Feb. 17 at 12:23 PM

$CRVO Pre-revenue biotech; early-stage ophthalmology pipeline.

0 · Reply

TradeNiko Feb. 17 at 8:50 AM

$CRVO Micro-cap biotech; early-stage

0 · Reply

BPler Feb. 14 at 1:45 PM

$CRVO Insider buying yesterday reported? There were some notifications with F13 last evening

1 · Reply

BPler Feb. 13 at 8:38 AM

$CRVO And with next earnings call we will probably also get an update on financing. I hope they aim for Revenue Interest Financing (RIF), as on October 28, 2025, CervoMed CEO John Alam, M.D., explicitly stated that the company is exploring external growth opportunities. "David's deep industry knowledge and proven track record supporting successful pipeline and commercial development, partnering, and M&A will be invaluable as we progress our planned Phase 3 program in DLB and evaluate strategic and business development initiatives."

1 · Reply

BPler Feb. 13 at 8:36 AM

$CRVO New positions reported yesterday in F13: 14.330 Shares - Hrt Financial Lp 11.076 Shares - Jane Street Group, Llc 13.951 Shares - Dimensional Fund Advisors Lp $BLK Blackrock Inc. confirmed they still have around 50.000 shares as well. https://fintel.io/de/so/us/crvo

0 · Reply

Messerschmittbf109 Feb. 12 at 8:33 PM

$CRVO $MS I laugh 😂

1 · Reply

Messerschmittbf109 Feb. 12 at 4:50 PM

$CRVO laundry machine… for sure Months of silence after just a pump and dump situation Similar China stock

0 · Reply

Messerschmittbf109 Feb. 12 at 4:20 PM

$CRVO these are parasites Bad people

0 · Reply

Scorpole Feb. 12 at 4:05 PM

$CRVO For 2 months ago the offering price could have been $4,50. Today $2. In 2 months $1.

3 · Reply

Market Cap	45.62M
Revenue (ttm)	9.74M
Net Income (ttm)	-16.29M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-167.25%
Debt to Equity Ratio	0.00

Volume	83,400
Avg Vol	68,004
Day's Range	N/A - N/A
Shares Out	9.25M
Stochastic %K	42%
Beta	-0.82
Analysts	Strong Sell
Price Target	$22.43